Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability

Toshiaki Ishikawa, Tomonobu Fujita, Yuriko Matsuzaki, Satoshi Okabe, Yasuhito Yuasa, Takehisa Iwai, Yutaka Kawakami

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Colorectal cancers with microsatellite instability (MSI+ CRCs) caused by dysfunction of DNA mismatch repair have unique clinicopathological characteristics including good prognosis with T-cell infiltration in tumor. To identify tumor antigens that induce immune response against MSI+ CRC, SEREX (serological analysis of recombinant cDNA expression cloning) was applied. By screening a λ phage cDNA library constructed from three MSI+ CRC cell lines with serum from a patient with MSI+ CRC with abundant T-cell infiltrates in tumor, 64 antigens were isolated. Immunogenicity of each antigen was evaluated by screening sera from patients with various cancers and from healthy individuals, and specific IgG antibodies (Abs) for 49 antigens were detected only in MSI+ CRC patients. A frameshift mutation in the repetitive G sequences (microsatellite) in the coding region of CDX2, one of the identified antigens, was found in the tumor tissue of the patient who had anti-CDX2 serum Ab. The Ab recognized both the COOH-terminal tumor-specific peptides created by the frameshift mutation and the NH2-terminal normal peptides of CDX2 when Western blot analysis was performed using various bacterial recombinant CDX2 proteins including the normal and altered peptides, which indicated that immune response could be raised against tumor-specific peptides generated through MSI. The anti-CDX2 Ab was detected only in the patient with the CDX2 frameshift mutation in tumor and disappeared 7 years after the curative resection, suggesting that this immune response may also be useful as a tumor marker. No altered subcellular localization and transcription ability was demonstrated in the mutated CDX2, although decreased expression was suggested in immunohistochemical analysis. Therefore, tumor-specific peptides generated by MSI may be involved in antitumor immune responses and may be useful for the development of diagnostic and therapeutic methods for patients with MSI+ CRC.

Original languageEnglish
Pages (from-to)5564-5572
Number of pages9
JournalCancer Research
Volume63
Issue number17
Publication statusPublished - 2003 Sep 1

Fingerprint

Microsatellite Instability
Colonic Neoplasms
Peptides
Frameshift Mutation
Neoplasms
Neoplasm Antigens
Antigens
Serum
T-Lymphocytes
DNA Mismatch Repair
Bacterial Proteins
N-methylsuccinimide
Nucleic Acid Repetitive Sequences
Tumor Biomarkers
Gene Library
Recombinant Proteins
Microsatellite Repeats
Bacteriophages
Organism Cloning
Colorectal Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ishikawa, T., Fujita, T., Matsuzaki, Y., Okabe, S., Yuasa, Y., Iwai, T., & Kawakami, Y. (2003). Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Research, 63(17), 5564-5572.

Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. / Ishikawa, Toshiaki; Fujita, Tomonobu; Matsuzaki, Yuriko; Okabe, Satoshi; Yuasa, Yasuhito; Iwai, Takehisa; Kawakami, Yutaka.

In: Cancer Research, Vol. 63, No. 17, 01.09.2003, p. 5564-5572.

Research output: Contribution to journalArticle

Ishikawa, T, Fujita, T, Matsuzaki, Y, Okabe, S, Yuasa, Y, Iwai, T & Kawakami, Y 2003, 'Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability', Cancer Research, vol. 63, no. 17, pp. 5564-5572.
Ishikawa, Toshiaki ; Fujita, Tomonobu ; Matsuzaki, Yuriko ; Okabe, Satoshi ; Yuasa, Yasuhito ; Iwai, Takehisa ; Kawakami, Yutaka. / Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. In: Cancer Research. 2003 ; Vol. 63, No. 17. pp. 5564-5572.
@article{27e572a5dfde46e3bef0f8fa8d6fcec1,
title = "Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability",
abstract = "Colorectal cancers with microsatellite instability (MSI+ CRCs) caused by dysfunction of DNA mismatch repair have unique clinicopathological characteristics including good prognosis with T-cell infiltration in tumor. To identify tumor antigens that induce immune response against MSI+ CRC, SEREX (serological analysis of recombinant cDNA expression cloning) was applied. By screening a λ phage cDNA library constructed from three MSI+ CRC cell lines with serum from a patient with MSI+ CRC with abundant T-cell infiltrates in tumor, 64 antigens were isolated. Immunogenicity of each antigen was evaluated by screening sera from patients with various cancers and from healthy individuals, and specific IgG antibodies (Abs) for 49 antigens were detected only in MSI+ CRC patients. A frameshift mutation in the repetitive G sequences (microsatellite) in the coding region of CDX2, one of the identified antigens, was found in the tumor tissue of the patient who had anti-CDX2 serum Ab. The Ab recognized both the COOH-terminal tumor-specific peptides created by the frameshift mutation and the NH2-terminal normal peptides of CDX2 when Western blot analysis was performed using various bacterial recombinant CDX2 proteins including the normal and altered peptides, which indicated that immune response could be raised against tumor-specific peptides generated through MSI. The anti-CDX2 Ab was detected only in the patient with the CDX2 frameshift mutation in tumor and disappeared 7 years after the curative resection, suggesting that this immune response may also be useful as a tumor marker. No altered subcellular localization and transcription ability was demonstrated in the mutated CDX2, although decreased expression was suggested in immunohistochemical analysis. Therefore, tumor-specific peptides generated by MSI may be involved in antitumor immune responses and may be useful for the development of diagnostic and therapeutic methods for patients with MSI+ CRC.",
author = "Toshiaki Ishikawa and Tomonobu Fujita and Yuriko Matsuzaki and Satoshi Okabe and Yasuhito Yuasa and Takehisa Iwai and Yutaka Kawakami",
year = "2003",
month = "9",
day = "1",
language = "English",
volume = "63",
pages = "5564--5572",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability

AU - Ishikawa, Toshiaki

AU - Fujita, Tomonobu

AU - Matsuzaki, Yuriko

AU - Okabe, Satoshi

AU - Yuasa, Yasuhito

AU - Iwai, Takehisa

AU - Kawakami, Yutaka

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Colorectal cancers with microsatellite instability (MSI+ CRCs) caused by dysfunction of DNA mismatch repair have unique clinicopathological characteristics including good prognosis with T-cell infiltration in tumor. To identify tumor antigens that induce immune response against MSI+ CRC, SEREX (serological analysis of recombinant cDNA expression cloning) was applied. By screening a λ phage cDNA library constructed from three MSI+ CRC cell lines with serum from a patient with MSI+ CRC with abundant T-cell infiltrates in tumor, 64 antigens were isolated. Immunogenicity of each antigen was evaluated by screening sera from patients with various cancers and from healthy individuals, and specific IgG antibodies (Abs) for 49 antigens were detected only in MSI+ CRC patients. A frameshift mutation in the repetitive G sequences (microsatellite) in the coding region of CDX2, one of the identified antigens, was found in the tumor tissue of the patient who had anti-CDX2 serum Ab. The Ab recognized both the COOH-terminal tumor-specific peptides created by the frameshift mutation and the NH2-terminal normal peptides of CDX2 when Western blot analysis was performed using various bacterial recombinant CDX2 proteins including the normal and altered peptides, which indicated that immune response could be raised against tumor-specific peptides generated through MSI. The anti-CDX2 Ab was detected only in the patient with the CDX2 frameshift mutation in tumor and disappeared 7 years after the curative resection, suggesting that this immune response may also be useful as a tumor marker. No altered subcellular localization and transcription ability was demonstrated in the mutated CDX2, although decreased expression was suggested in immunohistochemical analysis. Therefore, tumor-specific peptides generated by MSI may be involved in antitumor immune responses and may be useful for the development of diagnostic and therapeutic methods for patients with MSI+ CRC.

AB - Colorectal cancers with microsatellite instability (MSI+ CRCs) caused by dysfunction of DNA mismatch repair have unique clinicopathological characteristics including good prognosis with T-cell infiltration in tumor. To identify tumor antigens that induce immune response against MSI+ CRC, SEREX (serological analysis of recombinant cDNA expression cloning) was applied. By screening a λ phage cDNA library constructed from three MSI+ CRC cell lines with serum from a patient with MSI+ CRC with abundant T-cell infiltrates in tumor, 64 antigens were isolated. Immunogenicity of each antigen was evaluated by screening sera from patients with various cancers and from healthy individuals, and specific IgG antibodies (Abs) for 49 antigens were detected only in MSI+ CRC patients. A frameshift mutation in the repetitive G sequences (microsatellite) in the coding region of CDX2, one of the identified antigens, was found in the tumor tissue of the patient who had anti-CDX2 serum Ab. The Ab recognized both the COOH-terminal tumor-specific peptides created by the frameshift mutation and the NH2-terminal normal peptides of CDX2 when Western blot analysis was performed using various bacterial recombinant CDX2 proteins including the normal and altered peptides, which indicated that immune response could be raised against tumor-specific peptides generated through MSI. The anti-CDX2 Ab was detected only in the patient with the CDX2 frameshift mutation in tumor and disappeared 7 years after the curative resection, suggesting that this immune response may also be useful as a tumor marker. No altered subcellular localization and transcription ability was demonstrated in the mutated CDX2, although decreased expression was suggested in immunohistochemical analysis. Therefore, tumor-specific peptides generated by MSI may be involved in antitumor immune responses and may be useful for the development of diagnostic and therapeutic methods for patients with MSI+ CRC.

UR - http://www.scopus.com/inward/record.url?scp=0141815907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141815907&partnerID=8YFLogxK

M3 - Article

C2 - 14500396

AN - SCOPUS:0141815907

VL - 63

SP - 5564

EP - 5572

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -